On 3/31/25, Catalyst Biosciences Inc (NASDAQ: GYRE) stock suffered a major decline of -15.3%, closing at $7.72. Moreover, trading volume in this decline was exceptionally high at 326% of normal. Relative to the market the stock has been weak over the last nine months and has declined -20.5% during the last week.
Current PriceTarget Research Rating
Catalyst Biosciences is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment